A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer. (NCT05024097)
🩺 Plain-English Summary (8th-Grade Level)
Enrolled patients will receive upfront (week 1) short-course radiotherapy to gross pelvic disease (25Gy in 5fx) in combination with AB928 (150 mg orally, once daily as part of a continuous dose regimen). This will be followed by consolidation chemotherapy (weeks 3-20) with mFOLFOX x9 cycles in combination with AB928 and AB122.
Who can join: Review the eligibility criteria below.
Location: Weill Cornell Medical College — New York, New York
Age range: 18 Years to 90 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- Weill Cornell Medical College — New York, New York
- Brooklyn Methodist Hospital - NewYork Presbyterian — New York, New York
- New York Presbyterian Hospital - Queens — New York, New York
📞 Contact the Study Coordinator
Phone: (646) 962-3110
Email: fgr4002@med.cornell.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Rectal Cancer
- Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management — Irvine, California
- High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial) — Tampa, Florida
- Microbiome and Rectal Cancer — Tampa, Florida
- Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence — Cleveland, Ohio
- Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial — St Louis, Missouri
- Multicenter Phase II Study of Transanal TME (taTME) — Los Angeles, California
Explore by condition: All Rectal Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.